Country for PR: China
Contributor: PR Newswire Asia (China)
Thursday, August 05 2021 - 12:46
AsiaNet
Over 3,000 Units of HFNC Delivered to Poland and Peru, Micomme Medical Helps the World Fight Against COVID-19 Pandemic
CHANGSHA, China, Aug. 5, 2021/PRNewswire-AsiaNet/--

Recently, Micomme has associated with Polish and Peruvian partners to 
accomplish the government centralized purchase of 1,600 and 1,500 units of HFNC 
respectively. Both purchases are strategic material reserves of the local 
governments. The global pandemic is still ongoing, and the safety of people's 
lives is the primary goal pursued by governments. The projects also reflect the 
foresight and determination of the local governments. Both purchases were 
delivered in June 2021.

As the leading non-invasive respiratory therapy company in China, Micomme 
Medical launched their first transnasal High-Flow Nasal Cannula Oxygen Therapy 
Device (hereinafter referred to as HFNC) OH-70C in 2017. At the beginning of 
the pandemic outbreak, Micomme Medical responded quickly during the traditional 
Chinese Spring Festival. All employees returned to work from holiday, the 
production line was fully activated, and more than 5,000 units of HFNC were 
sent to Wuhan immediately. In 2020, Micomme achieved more than 10,000 HFNC 
installations worldwide (China not included), and helped countries around the 
world fight against COVID-19 with a production capacity of 500 units per day.

The transnasal High-Flow Nasal Cannula Oxygen Therapy Device is the machine 
recommended by WHO and related international guidelines for the treatment of 
patients with COVID-19. It aims to quickly increase the patient's oxygen 
saturation (SpO2) and improve the symptoms of hypoxia in patients by providing 
a high-flow air-oxygen mixed gas to patients with a constant temperature, 
humidity and a constant oxygen concentration. As one of the first HFNC 
manufacture in China, Micomme has won the market's recognition with its 
excellent product quality and brilliant product performance. In the battle 
against COVID-19, Micomme fulfills the commitment as the leading company.

For more details, please contact: market.intl@micomme.com 

Reference: 

www.who.int/publications/i/item/clinical-care-of-severe-acute-respiratory-infections-tool-kit 
 
www.who.int/publications/i/item/technical-specifications-for-invasive-and-non-invasive-ventilaotrs-for-covid-19 


Source: Micomme
Translations

Japanese